期刊文献+

塞瓦停治疗高脂血症的临床经验

RANDOMIZED CONTROLLED CLINICAL TRIAL OF SIMVASTATIN COMPARED WITH GEMFIBROZIL
下载PDF
导出
摘要 比较研究了塞瓦停(simvastatin、塞组)与吉非罗齐(gemfibrozil、吉组)治疗高脂血症的效应及安全性。108例高胆固醇血症者,给以低脂饮食后4周再次检测总胆固醇(TC)仍≥230mg/dl者作为治疗对象。所有患者随机分二组,一组服塞瓦停从10mg/晚或增至10~20mg每日1—2次;另一组服吉非罗齐600mg一日二次。治疗12周后塞组TC、LDL—C(低密度脂蛋白胆固醇)、TG(总甘油三酯)、Apo B(载脂蛋白B)、TC/HDL—C(总胆固醇/高密度脂蛋白胆固醇比值)分别下降30.84,40.76,29.08,20.54及38.77%(p<0.01);吉组分别下降21.9,23.07,54.99,11.55及33.29%(P<0.01)。塞组TC、LDL—C、Apo B下降明显优于吉组,而吉组降TG优于塞组,HDL—C升高亦优于塞组(p<0.01)。两药副作用均不显著,吉非罗齐服后发生过敏性皮疹一例未计入本研究外,无患者退出治疗。 The efficacy and tolerability of simvastatin compared with gemfibrozil in hypercholesterolemia were conducted by the two clinical research centers. 108 adult patients were included in the study. All patients had still documented blood cholesterol > 230mg/dl after a lipid-lowing diet for 4 weeks. The patienis were divided into two groups. One group received increasing 3 doses from 10mg at night to 10 or 20mg twice daily, and the other group received 600mg of gemfibrozil twice daily. After 12 weeks, the mean reductions of simvastatin group in TC, LDL-C, TG, Apo B and TC/HDL-C were by 30. 48, 40. 76,29. 08, 20. 54 and 38. 77% respectively (p<0. 01). Gemfibrozil group reduced by 21. 91, 23. 07, 54. 99, 11. 55 and 33. 29% respectively (p<0. 01). Efficacy of simvastatin group was better than that of gemfibrozil group for lowing TC, LDL-C, Apo B (p<0. 01), but gemfibrozil group was better than simvastatin for lowing TG (p<0. 01). As for increasing HDL-C, gemfibrozil showed better efficacy than that of simvastatin at the end of the 12th week (p<0. 01). Side effects attributable to both drugs were minimal, with no patient withdrawn from the study, but simvastatin is better tolerated than gemfibrozil.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 1993年第1期18-24,共7页 The Chinese Journal of Clinical Pharmacology
关键词 塞瓦停 吉非罗齐 高血脂症 Simvastatin gemfibrozil hypercholesterolemia
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部